Panno's thoughts on License

Author’s reply »Mixed thoughts. The licence deal is a good indication that transfection rates in the TT-034 trial are good (and probably much better than some other scientists had predicted) but there was no mention of HBV. The idea was that, if TT-034 proved to be successful, the same vector would be used for HBV. This could just be an oversight but confirmation that the same vector is going to be used for HBV would have provided more confidence that the HBV program can advance.